Abstract:Background: It has been more than a year since the whole world is struggling with COVID-19 pandemic and may experience resurgences in the near future. Along with severe pneumonia, this disease is notorious for extensive thromboembolic manifestations. That is why experts advocated aggressive anticoagulation as a part of the therapy since the beginning. However, from May 2020 onwards, cases of heparin-induced thrombocytopenia (HIT) are being reported. HIT in itself is an autoimmune entity leading to life-threatening thrombosis in the setting of thrombocytopenia. Continuation of heparin can have disastrous consequences in case of unrecognized HIT. Hence, timely recognition of HIT is of utmost value to modify the anticoagulation strategy and salvaging lives. We performed a systemic review trying to find all reported cases of HIT in COVID-19. Methods: It involved extensive search of the databases including PubMed, Google Scholar, Scopus, and Embase in an attempt to find all reported literature in the last 1 year (November 1, 2019-December 25, 2020) using keywords in various combinations. Literature search resulted in a total of 27 articles and 12 articles were finally selected based on the study design and their relevance pertaining to the intervention done and the outcome of interest. Results: A total of 35 patients were included (mean age 56.7 ± 12.8 years, male-to-female ratio = 2:1). The most frequent comorbidity was hypertension. Fifty-seven percent of cases were with low-molecular weight heparin and the rest with unfractionated heparin. Confirmatory functional assay was done in 85.7% of cases (67% by serotonin-release assay [SRA] and 33% by heparin-induced platelet aggregation [HIPA]). All cases tested with HIPA were positive, while with SRA, only 30% were positive. The most common alternate anticoagulation used was argatroban infusion. The new arterial thrombotic event was seen in only 5.7% of cases as repeat myocardial infarction, stroke, and splenic infarction, while clinically significant bleeding was seen in 17.1% of cases. Fifty percent of bleeding episodes were seen where conventional doses of argatroban were used, while no mortality was seen with low-dose argatroban infusion. However, only 45.7% of patients were discharged, 31.4% of patients died, while the outcome was pending for 23% of patients. Conclusion: Severe endotheliitis and immune dysregulation giving rise to HIT antibodies and antiphospholipid antibodies have been demonstrated in COVID-19 and modifying our therapy becomes indispensable when it is pathogenic with potentially fatal consequences. In the light of interim results of REMAP-CAP study in severe COVID-19 cases where heparin does not improve the outcome, the present anticoagulation strategy needs re-evaluation. Unrecognized HIT can be catastrophic and close clinical monitoring is required for patients on heparin therapy.

Considering heparin-related coagulation status when providing motor exercise in patients with COVID-19

Hemorrhage and Venous Thromboembolism in Critically Ill Patients with COVID-19

The Potential Role of Heparin in Patients With COVID-19: Beyond the Anticoagulant Effect. A Review

Heparin Therapy Improving Hypoxia in COVID-19 Patients – A Case Series

Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients

Anticoagulant and antiarrhythmic effects of heparin in the treatment of COVID‐19 patients

Comprehensive Landscape of Heparin Therapy for COVID-19

Anticoagulation for COVID-19 Patients: A Bird's-Eye View

Heparin-Induced Thrombocytopenia in COVID-19: A Systematic Review

Potential benefits of anticoagulant doses of low molecular weight heparin in COVID-19: An observational retrospective study

Anticoagulation Options for Coronavirus Disease 2019 (COVID-19)-Induced Coagulopathy

Safety of intermediate dose of low molecular weight heparin in COVID-19 patients

Another new application of heparin in COVID-19: more than anticoagulation and antiviral

Low Molecular Weight Heparin Protects Lung, Renal and Microcirculation Function in Patients with Covid-19 Pneumonia

Low Molecular Weight Heparin Protects Lung, Renal and Microcirculation Function&nbsp;in Patients with Covid-19 Pneumonia

Heparin in COVID-19 Patients Is Associated with Reduced In-Hospital Mortality: The Multicenter Italian CORIST Study

Role of Therapeutic Anticoagulation in COVID-19: The Current Situation

Non-anticoagulant heparin derivatives for COVID-19 treatment

Anticoagulation Strategies in Critically Ill Patients With SARS-CoV-2 Infection: The Role of Direct Thrombin Inhibitors

Heparin-induced thrombocytopenia is associated with a high risk of mortality in critical COVID-19 patients receiving heparin-involved treatment

COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation